

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHINA ISOTOPE & RADIATION CORPORATION

中國同輻股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1763)

VOLUNTARY ANNOUNCEMENT

NUCLEAR ENERGY DEVELOPMENT PROJECT UNDERTAKEN BY CIRC PASSING THE ASSESSMENT WITH A RATING OF “OUTSTANDING”

This announcement is made on a voluntary basis by China Isotope & Radiation Corporation (the “**Company**”) to keep shareholders and potential investors informed of the latest business developments of the Company.

The board of directors (the “**Board**”) of the Company is pleased to announce that recently, Beijing Municipal Office of Science, Technology and Industry for National Defense organised an assessment experts group to conduct the assessment of a nuclear energy development and research project of the State Administration of Science, Technology and Industry for National Defense jointly undertaken by the Company and HTA Co., Ltd. (原子高科股份有限公司), which is titled “Research on Preparation Technology and Related Drugs of Key Nuclide ⁶⁴Cu for Integrated Diagnosis and Treatment” (the “**Project**”). The assessment experts group unanimously agreed that the Project has passed the assessment with a rating of “Outstanding”.

In 2021, eight ministries and commissions including the China Atomic Energy Authority have listed the research on ⁶⁴Cu nuclide preparation technology in the “Medium and Long-term Development Plan for Medical Isotopes (2021-2035)” (《醫用同位素中長期發展規劃(2021-2035年)》). At present, a number of domestic radiopharmaceutical manufacturers and research institutions have an urgent demand for the supply of ⁶⁴Cu nuclide, which has achieved independent commercial supply and has been provided to many research institutions for use with good application results.

Through research, the Project has mastered the key technology for the preparation of ^{64}Cu nuclide and has realised mass production thereof. ^{64}Cu nuclide products have good stability and quality indicators that meet the requirements for medicinal use, which directly addresses the short supply of ^{64}Cu nuclide, thereby effectively promoting the development and transformation of ^{64}Cu labeled drugs in China and benefiting cancer patients.

By order of the Board
China Isotope & Radiation Corporation
Wang Suohui
Chairman

Beijing, the PRC, 7 December 2023

As at the date of this announcement, the Board comprises Mr. Wang Suohui, Mr. Xu Hongchao and Mr. Du Jin as executive Directors; Mr. Chen Shoulei, Mr. Ding Jianmin, Ms. Chang Jinyu and Ms. Liu Xiuhong as non-executive Directors; and Mr. Poon Chiu Kwok, Mr. Tian Jiahe, Ms. Chen Jingshan and Mr. Lu Chuang as independent non-executive Directors.